Allogeneic stem cell therapy (ViaCyte)

N/A

Report date: 2023/10/19 20:00:40

Base Information

Drug NameAllogeneic stem cell therapy (ViaCyte)
Drug Alias NameEncapsulated islet cell transplantation therapy - ViaCytePancreatic beta cell replacement therapy - ViaCyteEncapsulated pancreatic cell transplantation therapy - ViaCyteEncapsulated human islet cell therapy - ViaCyteEncapsulated pancreatic cell therapy - ViaCyte +[9] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Embryonic stem cells therapy
Mechanisms of ActionPancreatic beta cell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViacyte IncW. L. Gore & AssociatesJdrf
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViacyte Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A